Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2013-003859-37Phase 3
Phase 3, open-label, single-arm trial of acellular pertussis vaccine in diphtheria, Tetanus and pertussis, sponsored by GSK. Primary endpoint: Safety and reactogenicity after booster vaccination.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2013-003859-37.